EICHORCondition: Multiple Myeloma · Sponsor: Janssen Research & Development, LLC
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | — |
| Winship Cancer Institute Emory University | Atlanta, Georgia, United States | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis, Indiana, United States | — |
| Washington University School Of Medicine | St Louis, Missouri, United States | — |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | — |
| Memorial Sloan-Kettering Cancer Center | New York, New York, United States | — |
| Weill Cornell Medical College | New York, New York, United States | — |
| Levine Cancer Institute | Charlotte, North Carolina, United States | — |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | — |
| Tennessee Oncology | Nashville, Tennessee, United States | — |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04722146